Presentation (CTI)

OBJECTIVES: Multiple Sclerosis (MS) is an epidemiological and socio-economic challenge in Algeria especially for the young adults in the prime of their productive lives. To address this, it is critical to evaluate the medical-economic, budgetary and organizational impact of introducing the Subcutaneous (SC) formulation of Ocrelizumab in Algeria for MS treatment.
METHODS: The study utilizes a hybrid multicenter observational design. The clinical efficacy and safety are established using data from the pivotal OCARINA II trial. A cohort of 25 patients receiving treatment with disease-modifying therapies was used, quantified the medical, paramedical, and logistical resources required during the intermittent administration of Ocrelizumab and Natalizumab. Data were collected at Ali Ait Idir Hospital’s Neurology Department adding up to the already existing data collected from different centres using structured questionnaires for healthcare professionals. Based on the collected data, a 5- year prospective Budget Impact Analysis and Service Impact Model (SIM) was conducted to compare 2 models, a reference baseline (current scenario) and a prospective model (New Mix); to project the financial and human outcomes of adopting SC ocrelizumab.
RESULTS: Clinical evidence confirms SC Ocrelizumab delivers comparable efficacy to IV via a 10-minute injection. Chronometric analysis revealed that the subcutaneous pathway reduces total patient stay by -56.9%, day-hospital chair occupancy by -65.7%, and active nursing time by -66.7%, and also -62.4% reduction in infrastructure burden. Economically, Annual cost savings are projected to exceed 2.5 billion DZD (the equivalent of 18.74 million USD) from Year 1 across all capacity allocations.
CONCLUSIONS: Transitioning to SC Ocrelizumab provides a highly favorable socio-economic equation for Algeria; by reducing per-patient time, optimizing physical resources, enabling substantial potential growth, and ensuring major economic cost savings.